ATE80465T1 - Diagnose von fettleibigkeit, hervorgerufen durch eine genetische abnormalitaet, und verfahren zur therapeutischen behandlung von genetisch bedingter fettleibigkeit. - Google Patents

Diagnose von fettleibigkeit, hervorgerufen durch eine genetische abnormalitaet, und verfahren zur therapeutischen behandlung von genetisch bedingter fettleibigkeit.

Info

Publication number
ATE80465T1
ATE80465T1 AT88903655T AT88903655T ATE80465T1 AT E80465 T1 ATE80465 T1 AT E80465T1 AT 88903655 T AT88903655 T AT 88903655T AT 88903655 T AT88903655 T AT 88903655T AT E80465 T1 ATE80465 T1 AT E80465T1
Authority
AT
Austria
Prior art keywords
genetic
obesity
abnormality
diagnosis
methods
Prior art date
Application number
AT88903655T
Other languages
English (en)
Inventor
Jeffrey S Flier
Bruce M Spiegelman
Original Assignee
Beth Israel Hospital
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Dana Farber Cancer Inst Inc filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE80465T1 publication Critical patent/ATE80465T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT88903655T 1987-04-02 1988-03-29 Diagnose von fettleibigkeit, hervorgerufen durch eine genetische abnormalitaet, und verfahren zur therapeutischen behandlung von genetisch bedingter fettleibigkeit. ATE80465T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3420387A 1987-04-02 1987-04-02
EP88903655A EP0382720B1 (de) 1987-04-02 1988-03-29 Diagnose von fettleibigkeit, hervorgerufen durch eine genetische abnormalität, und verfahren zur therapeutischen behandlung von genetisch bedingter fettleibigkeit
PCT/US1988/000999 WO1988007681A1 (en) 1987-04-02 1988-03-29 Diagnosing obesity caused by a genetic abnormality and method of therapeutically treating genetically caused obesity

Publications (1)

Publication Number Publication Date
ATE80465T1 true ATE80465T1 (de) 1992-09-15

Family

ID=21874944

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88903655T ATE80465T1 (de) 1987-04-02 1988-03-29 Diagnose von fettleibigkeit, hervorgerufen durch eine genetische abnormalitaet, und verfahren zur therapeutischen behandlung von genetisch bedingter fettleibigkeit.

Country Status (13)

Country Link
EP (2) EP0382720B1 (de)
JP (1) JPH02503229A (de)
AT (1) ATE80465T1 (de)
AU (1) AU606946B2 (de)
DE (1) DE3874543T2 (de)
DK (1) DK675388A (de)
ES (1) ES2046325T3 (de)
FI (1) FI894592A0 (de)
GR (1) GR3005716T3 (de)
IL (1) IL85897A0 (de)
NO (1) NO885360L (de)
WO (1) WO1988007681A1 (de)
ZA (1) ZA882288B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084062A1 (en) * 1990-06-01 1991-12-02 Ginette Serrero Mammalian adipogenic factors
US20060263774A1 (en) * 2002-11-01 2006-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US10328131B2 (en) 2014-03-13 2019-06-25 Dana-Farber Cancer Institute, Inc. Compositions and methods for regulating pancreatic beta cell function using adipsin
DE102014107380A1 (de) 2014-05-26 2015-11-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Verfahren zur Diagnose einer durch den alternativen Weg des Komplementsystems vermittelten Krankheit oder eines Risikos hierfür

Also Published As

Publication number Publication date
ZA882288B (en) 1988-12-28
DK675388D0 (da) 1988-12-02
IL85897A0 (en) 1988-09-30
EP0287509B1 (de) 1992-09-16
DE3874543T2 (de) 1993-02-04
AU1591388A (en) 1988-11-02
EP0382720A1 (de) 1990-08-22
EP0287509A1 (de) 1988-10-19
EP0382720B1 (de) 1992-09-09
FI894592A7 (fi) 1989-09-28
EP0382720A4 (en) 1991-01-02
AU606946B2 (en) 1991-02-21
FI894592L (fi) 1989-09-28
NO885360L (no) 1989-02-01
ES2046325T3 (es) 1994-02-01
FI894592A0 (fi) 1989-09-28
WO1988007681A1 (en) 1988-10-06
DK675388A (da) 1988-12-02
JPH02503229A (ja) 1990-10-04
GR3005716T3 (de) 1993-06-07
NO885360D0 (no) 1988-12-01
DE3874543D1 (de) 1992-10-15

Similar Documents

Publication Publication Date Title
DE69729473D1 (de) Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
ATE79261T1 (de) Verfahren zur behandlung von magen-darmstoerungen.
DE69830185D1 (de) Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
ATE163767T1 (de) Verfahren zur diagnose und zur überprüfung von sepsis
DE3587266D1 (de) Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut.
ES2073425T3 (es) Una nueva glicoproteina de tipo trombomodulina susceptible de ser obtenida a partir de la orina.
DE69434566D1 (de) Diagnose und behandlung von supravalvular aortic stenosis
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
ATE80465T1 (de) Diagnose von fettleibigkeit, hervorgerufen durch eine genetische abnormalitaet, und verfahren zur therapeutischen behandlung von genetisch bedingter fettleibigkeit.
Nankai et al. Platelet [3H] imipramine binding in depressed patients and its circadian variations in healthy controls
Swedberg et al. Wound botulism
Rao et al. Immunological implications of xenogeneic and allogeneic transplantation to neonatal rats
ATE312914T1 (de) Rdgb-proteine
Green Immunoaugmentative therapy: An unproven cancer treatment
Weber et al. A Double-blind Placebo Controlled Crossover Study in Patients With Peripheral Vascular Diseases, Using a New Capillary Viscometer.
SU787995A1 (ru) Способ дифференцировани т и в лимфоцитов человека
ATE45224T1 (de) Verfahren zur diagnose von a.i.d.s.
SU1247014A1 (ru) Способ диагностики болезни Вильсона-Коновалова
Elliott Studies on the Motor Cells of the Spinal Cord: V. Poliomyelitic Lesions in the Spinal Motor Nuclei in Acute Cases
Corcoran Essential Hypertension
Chandra et al. 691 IMMUNOCOMPETENCE IN OBESITY
KRANTZ A TWIN STUDY OF NEUROPSYCHOLOGICAL ABILITIES (LEARNING DISABILITIES, HALSTEAD-REITAN)
Walton The science of clinical neurology
DE69402683D1 (de) Nachweis synthetischer oligonucleotide extrahiert aus körperflüssigkeiten oder geweben:

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee